Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma
Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma
复制标题
DOI：
10.1046/j.1440-1746.1999.01873.x
复制
发表时间：
1999-05-01
影响因子：
4.1
通讯作者：
Johnson, PJ
中科院分区：
文献类型：
--
作者：
Johnson, PJ
甲胎蛋白（AFP）在首次被描述35年后，仍然是判断其他标志物的金标准。大约75%的肝细胞癌（HCC）病例的血清水平高于参考范围10 ng/mL。在个体患者中，血清AFP水平表现为反映肿瘤质量。然而，AFP的特异性相对较低，因为在一些无并发症的慢性肝病患者中也发现了中度升高的水平。最近，已经开发了肿瘤特异性AFP测定。这些是基于AFP分子上的碳水化合物侧链，其在不同来源的AFP中表现出特征性差异。监测反应的治疗往往可以更有效地进行系列估计AFP比传统的成像技术。AFP对HCC的相对特异性也被用于检测循环HCC细胞和靶向基因治疗。
Thirty-five years after its first description, alpha-fetoprotein (AFP) remains the gold standard by which other markers are judged. Serum levels above the reference range of 10 ng/mL occur in approximately 75% of cases of hepatocellular carcinoma (HCC). In individual patients, the serum AFP level behaves as if it reflects tumour mass. However, the specificity of AFP is relatively low because moderately raised levels are also found in some patients with uncomplicated chronic liver disease. Recently, tumour-specific AFP assays have been developed. These are based on the carbohydrate side-chains on the AFP molecule which exhibit characteristic differences in AFP of different origins. Monitoring response to treatment may often be more effectively carried out by serial estimation of AFP than by conventional imaging techniques. The relative specificity of AFP for HCC has also been employed to detect circulating HCC cells and to target gene therapy.